Omnicell (NASDAQ:OMCL) Releases FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 1.650-1.850 for the period, compared to the consensus EPS estimate of 1.790. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Analysts Set New Price Targets

A number of brokerages recently issued reports on OMCL. Benchmark restated a “buy” rating and issued a $62.00 price target on shares of Omnicell in a research note on Tuesday. StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Barclays raised their price target on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Wells Fargo & Company lowered their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. raised their price target on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $52.33.

Omnicell Price Performance

OMCL stock traded up $0.78 on Friday, reaching $40.21. The company’s stock had a trading volume of 369,396 shares, compared to its average volume of 369,290. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The company has a market capitalization of $1.86 billion, a P/E ratio of -103.01, a price-to-earnings-growth ratio of 30.78 and a beta of 0.78. The firm has a fifty day moving average of $44.34 and a two-hundred day moving average of $43.20.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a positive return on equity of 2.55% and a negative net margin of 1.66%. As a group, equities analysts expect that Omnicell will post 0.94 EPS for the current fiscal year.

Insiders Place Their Bets

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.64% of the stock is owned by company insiders.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.